Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort

Authors

  • Irina Tsibulak Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Verena Wieser Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Hannah Welponer Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Katharina Leitner Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Hubert Hackl Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
  • Christian Marth Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Heidelinde Fiegl Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
  • Alain G. Zeimet Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria

DOI:

https://doi.org/10.1080/0284186X.2020.1841288

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2021-02-01

How to Cite

Tsibulak, I., Wieser, V., Welponer, H., Leitner, K., Hackl, H., Marth, C., … Zeimet, A. G. (2021). Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort. Acta Oncologica, 60(2), 187–190. https://doi.org/10.1080/0284186X.2020.1841288

Issue

Vol. 60 No. 2 (2021): Acta Oncologica

Section

Articles